SCHEMBL5002489

SCHEMBL5002489

CNS(=O)(=O)c1cccc(C=C2c3ccccc3CCc3ccccc32)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.62
NR3C1 P04150 1/20 0.62
PGR P06401 1/20 0.62
NR3C2 P08235 1/20 0.62
MAPT P10636 5/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
PKM P14618 1/20 0.43
ATM Q13315 1/20 0.43
MIF P14174 3/20 0.43
MAOB P27338 1/20 0.40
LMNA P02545 5/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 2/20 0.40
CYP3A4 P08684 2/20 0.40
SLC6A2 P23975 2/20 0.40
TP53 P04637 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4164989 0.85 NR3C2 (0.52) ARNR3C1PGRNR3C2MAPT
SCHEMBL4166513 0.85 AR (0.66) ARNR3C1PGRNR3C2MAPT
SCHEMBL4175440 0.82 AR (0.59) ARNR3C1PGRNR3C2MAPT
SCHEMBL4168200 0.82 AR (0.59) ARNR3C1PGRNR3C2MAPT
SCHEMBL4161563 0.82 AR (0.58) ARNR3C1PGRNR3C2MAPT
SCHEMBL4173954 0.80 PGR (0.73) ARNR3C1PGRNR3C2MEN1
SCHEMBL4164904 0.78 NR3C1 (0.40) ARNR3C1PGRNR3C2L3MBTL1
SCHEMBL4164907 0.78 NR3C1 (0.40) ARNR3C1PGRNR3C2L3MBTL1
SCHEMBL4160670 0.76 NR3C1 (1.00) ARNR3C1PGRNR3C2MAPT
SCHEMBL4157439 0.76 AR (0.69) ARNR3C1PGRNR3C2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2006-03-23 US disclosed
WO-2004052847-A2 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS NR5A1, NR3C2, NR3C1 AR 48/4885NR3C1 3/4885PGR 54/4885
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators NR5A1, NR3C2, NR3C1 AR 45/4885NR3C1 3/4885PGR 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.